Research News and Market Data on COSM
Monthly subscription value of $1.83 million as of October 31, 2026, approximately $22.0 million on an annualized basis
12,532 active U.S. subscriptions as of October 31, 2026
October U.S. e-commerce total sales of $1.67 million, of which approximately $1.02 million, or 61%, was attributable to subscriptions
Approximately 19,100 orders in October from approximately 234,500 online store sessions
Continued momentum in November, with U.S. e-commerce sales continuing to grow significantly
CHICAGO, IL / ACCESS Newswire / November 11, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its U.S. direct-to-consumer subscription business reached $1,832,785 in monthly subscription value as of October 31, 2026, equivalent to approximately $22.0 million on an annualized basis. In October 2026, the Company’s U.S. e-commerce business recorded total sales of $1,673,004, of which $1,015,231 was attributable to subscriptions.
October 2026 Key Metrics
| Metric | October 2026 | Details |
| Monthly subscription value (as of October 31) | $1,832,785 | Approximately $22.0 million annualized |
| Active subscriptions (as of October 31) | 12,532 | Net growth of 11,544 during October |
| Product units in active subscriptions | 29,507 | Approximately 2.4 per subscription |
| Total sales | $1,673,004 | Including $1,015,231 attributable to subscriptions |
| Orders | Approximately 19,100 | From approximately 234,500 store sessions |
| Conversion rate | 7.72% | Share of store sessions resulting in an order |
Building a Recurring Revenue Base
Cosmos Health launched its U.S. subscription model in mid-July 2026 and began scaling it in mid-September. The Company’s products are sold through its own online stores directly to customers, who can choose a subscription for recurring delivery at checkout. Active subscriptions renew on a recurring basis, so every new subscriber can represent an ongoing customer relationship rather than a single sale.
Outlook for the Fourth Quarter
The Company has allocated an increased marketing budget to continue scaling its U.S. direct-to-consumer sales through the fourth quarter of 2026, including the holiday shopping season. Cosmos Health plans to expand digital customer acquisition, grow its subscription base and introduce additional products from its portfolio to its U.S. online stores. Momentum has continued into November, with U.S. e-commerce sales continuing to grow significantly.
Greg Siokas, CEO of Cosmos Health, stated: “Since we began scaling our U.S. subscription platform in mid-September, we have built a subscription business with $1.83 million in monthly subscription value, or approximately $22 million on an annualized basis. As of October 31, more than 12,500 subscriptions were active, with an average of approximately 2.4 products per subscription.
“We believe recurring revenue is among the most valuable revenue a consumer health company can build, and we plan to continue scaling our U.S. direct-to-consumer business through the fourth quarter and beyond.”
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Note: All figures are preliminary, unaudited operating data from the Company’s e-commerce and subscription platforms and may differ from amounts in its financial statements. Total sales include taxes and shipping, net of discounts, returns and fees. Monthly subscription value is the amount billable on active subscriptions in a month at standard renewal pricing as of October 31, 2026; the annualized figure is that value multiplied by twelve and is not a forecast. Subscription metrics are subject to cancellations and churn, and none of these metrics represent U.S. GAAP revenue. November statements reflect preliminary data; actual results may differ materially.
Investor Relations Contact:
BDG Communications
[email protected]
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
